G2 Inflammation Pty Ltd

Beijing University of Technology

G2 Therapies Ltd

Garvan Institute of Medical Research

Charles Reay Mackay

David Georges Zahra

Di Yu

Peter Whitfeld

Remy Michel Robert

Herbert Herzog

The invention relates to CXCR2, to antibodies and related fragments thereof for binding to CXCR2, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions.

CXCR2 antibodies and uses thereof

The invention relates to IL-21, to antibodies and related fragments thereof for binding to IL-21, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular inflammation, infection and oncology.

IL-21 agonist antibodies and methods of treatment using same

The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (IL-21) and uses thereof, e.g., in therapy.

Methods of treating cancer using an IL-21 agonist

IL-21 binding proteins

The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.

Methods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies

The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.

Methods of treatment with antibodies against the extracellular loops of C5aR

Humanized anti-C5aR antibodies

The present invention relates to improved antibodies which bind to C5aR and which are useful in diagnosis and therapeutic methods.

Anti-C5aR antibodies with improved properties

The present invention provides transgenic animals having a reduced level of expression of peptide YY (PYY) and drug screening platforms using the transgenic animals for identifying agonists and antagonists of PYY. The present invention further provides monoclonal antibodies that bind specifically to full-length PYY[1-36] or the processed form thereof i.e., PYY[3-36] and to diagnostic and drug screening platforms using the monoclonal antibodies. The invention has particular utility for the diagnosis of a predisposition or risk of a subject becoming obese, developing one or more pathologies associated with obesity, or developing a disease/disorder of bone tissue.

Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor

Monoclonal antibodies against extracellular loops of C5aR

The present invention relates to a method for producing antibodies and to antibodies produced by this method. In one embodiment the invention relates to a method for producing an antibody that binds to a polypeptide of a first species, the method comprising immunizing a mammal of a second species with cells derived from a transgenic mammal of the second species, wherein the polypeptide of the first species is expressed on the surface of the cells derived from the transgenic mammal.

Method for producing antibodies

The present invention relates to antibodies which bind to C5R and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5R other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5to C5R and functional consequences of neutrophil chemoattractant receptor activation.

Anti-C5aR antibodies and uses thereof

The present invention relates to transgenic non-human mammals comprising a polynucleotide encoding a human or humanized C5aR. The invention also relates to use of the transgenic non-human mammals in methods of screening for agonists, inverse agonists and antagonists of human C5aR and for testing efficacy of C5aR agonists, inverse agonists and antagonists in various animal models of disease.

Growing community of inventors

Vaucluse, Australia

Charles Reay Mackay